Dyslipidemia in diabetes patients
Atherogenic dyslipidemia increases CV risk in diabetes patients. Prof. Ray discusses the importance of dyslipidemia in these patients, the associated CV risk and new medical therapies to reduce this risk.
Video navigation menu
- Lipid-lowering therapies reduce CV risk in diabetes patients 00:26
- The concept of diabetic dyslipidemia explained 03:45
- The effect of alirocumab on non-HDL-c levels in the ODYSSEY DM-DYSLIPIDEMIA trial 05:46
- Evaluation of evolocumab on clinical endpoints in the FOURIER trial 09:47
Persons with diabetes have an increased CV risk, which is even further increased by atherogenic dyslipidemia. Statins and other lipid lowering therapies reduce CV risk in these patients. The effect of PCSK9 inhibitors on non-HDL-c levels and clinical events was demonstrated in patients with diabetes. This recording aims to explain the concept of dyslipidemia in diabetes patients and the results of the PCSK9 trials.
Kausik Ray, MD, is a cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.